Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 16, 2007

Alte Biosciences Licenses Technology for Depression Therapeutics from Duke

  • Alte Biosciences secured exclusive rights to IP developed at the Duke University Medical Center for drugs targeting late-onset depression and related disorders.

    The licensed technology is a patent based on findings by Ranga Krishnan, M.D., related to the relationship between cerebrovascular disease and the onset of depression in elderly individuals, a disease called vascular depression. Dr. Krishnan is professor and chairman of the department of psychiatry and behavioral sciences at Duke University Medical Center.

    The company will immediately focus on conducting the regulatory studies needed to advance the lead candidate, ARX-111, into a clinical proof-of-concept study within the next 12 months, according to Thomas Colatsky, Ph.D., CSO for Alte Biosciences.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »